View More Recent Stories

Aug 14, 2024 04:20PM Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c
Jul 29, 2024 07:32AM Arcutis Biotherapeutics (ARQT) Launches ZORYVE Cream 0.15% for the Treatment of Atopic Dermatitis
Jul 23, 2024 08:02AM Arcutis Biotherapeutics (ARQT) Submits Supplemental New Drug Application for ZORYVE Foam
Jul 23, 2024 05:54AM Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $19 at Mizuho
Jul 10, 2024 07:35AM TD Cowen Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT)
Jul 9, 2024 04:54PM Arcutis Biotherapeutics (ARQT) Announces FDA Approval of ZORYVE Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children above 6
Jul 9, 2024 08:43AM Mizuho Reiterates Outperform Rating on Arcutis Biotherapeutics Inc. (ARQT)
Jun 13, 2024 02:19PM Arcutis Biotherapeutics (ARQT) spreader active in July 10 and 12.50 calls
Jun 10, 2024 02:31PM Arcutis Biotherapeutics (ARQT) Announces New Long-Term Data of Roflumilast Cream 0.15%
View More Recent Stories